Soluble endoglin as a diagnosis glycoprotein in preeclampsia

Shaima Al-Kilan, Ekhlas Abdallah Hassan

Abstract


Background: Angiogenic factor imbalance, such as that caused by soluble endoglin (sEng), is a feature of preeclampsia. However, the connection between sEng and clinical and laboratory indicators, and the severity of preeclampsia is not entirely understood.

Methods:  Ninety subjects were incorporated in this study, 30 were healthy pregnant with mean age (35.6) years. (32) mild  Preeclampsia case with mean age (32.65) years preeclampsia, and (30) sever PE with mean age (32.65) wherever all women were more than 24 weeks of pregnancy. Mean blood pressure and level of proteinuria were used as indicators of the severity of the disease. ELISA was used to measure the levels of sEng in the serum. Serum lipid profile was measured by enzymatic methods. The qualitative dip-stick technique (CYBOWTM DFI Co Ltd, Republic of Korea) was used to assess the amount of urine protein.

Results : A substantial difference between the PE group's serum sEng concentration and that of the healthy subjects (p 0.001) could be seen. Serum sEng concentrations of patients with moderate PE and those with severe PE differed significantly. Additionally, there were strong positive relationships between the serum sEng concentration and the SBP and proteinuria. serum sEng levels, biochemical indicators, and other factors, however, did not significantly correlate. The diagnostic accuracy (86.2) in distinguishing mild PE from the healthy patient group was good thanks to the excellent area under the curve (AUC = 0.827, p < 0.0001).  

Conclusion: Levels of  sEng  in sera of PE patients were elevated. sEng was significantly correlated with PE patients.

Keywords: Soluble Endoglin; Preeclampsia; Proteinuria; Blood Pressure  


Full Text:

PDF

References


Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ. Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circulation research, (2002);90(12):1274-81.

Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, et al. Molecular evidence of placental hypoxia in preeclampsia. The Journal of Clinical Endocrinology & Metabolism, (2005);90(7):4299-308.

Turpin CA, Sakyi SA, Owiredu WK, Ephraim RK, Anto EO. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia. BMC pregnancy and childbirth, (2015);15:1-0.

Kim SY, Ryu HM, Yang JH, Kim MY, Han JY, et al. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. Journal of Korean medical science, (2007);22(5):873-7.

Osungbade KO, Ige OK. Public Health Perspectives of Preeclampsia in Developing Countries: Implication for Health System Strengthening, Journal of Pregnancy. (2011); 2011(481095):6.

Wilkinson J, Cole G. Preeclampsia knowledge among women in Utah. Hypertension in Pregnancy, (2018);37(1):18–24.

Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstetrical & Gynecological Survey, (2011);66(8):497–506.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. New England Journal of Medicine, (2004);350:672–683.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New England Journal of Medicine, (2006); 355:992–1005.

Leaños-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leaños R, Romero-Arauz JF, et al. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. Journal of Hypertension, (2012);30:2173–2181.

Rana S, Powe CE, Salahuddin S,V erlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation, (2012);125:911–919.

Leaños-Miranda A, Campos-Galicia I, Ramírez-Valenzuela K, Chinolla-Arellano ZL, Isordia-Salas I. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia. Hypertension, (2013);61:1118–1125

Leaños-Miranda A, Méndez-Aguilar F, Ramírez-Valenzuela KL, et al. Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes. Medicine (Baltimore), (2017);96:e6005e.

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P. Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. New England

Journal of Medicine, (2016);374(1):13-22.

Pece Barbara N, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the TGF-β superfamily. Journal of Biological Chemistry, (1999);274:584-94.

Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrology Dialysis Transplantation, (2006);21(11):3052-4.

Robinson CJ, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. American journal of obstetrics and gynecology, (2007);197(2):174-e1.

Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S. CD105 prevents apoptosis in hypoxic endothelial cells. Journal of cell science, (2003);116(13):2677-85.

Jerkic M, Rivas‐Elena JV, Prieto M, Carrón R, Sanz‐Rodríguez F, Pérez‐Barriocanal F, Rodríguez‐Barbero A, Bernabéu C, López‐Novoa JM. Endoglin regulates nitric oxide‐dependent vasodilatation. The FASEB Journal, (2004);18(3):609-11.

Venkatesha S, Toporsian M, Lam C, Hanai JI, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature medicine, (2006);12(6):642-9.

Leaños-Miranda A, Campos-Galicia I, Ramírez-Valenzuela KL, Chinolla-Arellano ZL, Isordia-Salas I. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia. Hypertension, (2013);61(5):1118-25.

Leaños-Miranda A, Méndez-Aguilar F, Ramírez-Valenzuela KL, Serrano-Rodríguez M, Berumen-Lechuga G, Molina-Pérez CJ, Isordia-Salas I, Campos-Galicia I. Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes. Medicine, (2017);96(4).

Perucci LO, Gomes KB, Freitas LG, Godoi LC, Alpoim PN, Pinheiro MB, Miranda AS, Teixeira AL, Dusse LM, Sousa LP. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PloS one, (2014);9(5):e97632.

Rana S, Cerdeira AS, Wenger J, Salahuddin S, Lim KH, Ralston SJ, Thadhani RI, Karumanchi SA. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PloS one, (2012);7(10):e48259.

Troisi R, Braekke K, Harsem NK, Hyer M, Hoover RN, Staff AC. Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. American journal of obstetrics and gynecology, (2008);199(6):653-e1.

Venkatesha S, Toporsian M, Lam C, Hanai JI, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature medicine, (2006);12(6):642-9..

Tjwa M, Luttun A, Autiero M, Carmeliet P. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell and tissue research, (2003);314:5-14.

Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. The Journal of Clinical Endocrinology & Metabolism, (2007);92(7):2672-9.

De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta obstetricia et gynecologica Scandinavica, (2008);87(8):837-42.

Lim JH, Kim SY, Park SY, Yang JH, Kim MY, Ryu HM. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstetrics & Gynecology, (2008);111(6):1403-9.

Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. American journal of obstetrics and gynecology, (2008); 199(3):266-e1.




DOI: http://dx.doi.org/10.62940/als.v11i3.1954

Refbacks

  • There are currently no refbacks.